Amgen Receives Positive CHMP Opinion For ABP 501 Biosimilar Adalimumab For The Treatment Of Certain Inflammatory Diseases

THOUSAND OAKS Calif. Jan. 27 2017 PRNewswire Amgen NASDAQAMGN today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion for the Marketing Authorization of ABP 501 biosi...